{"id":816328,"date":"2025-02-21T13:47:16","date_gmt":"2025-02-21T18:47:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-for-more-information-regn-2\/"},"modified":"2025-02-21T13:47:16","modified_gmt":"2025-02-21T18:47:16","slug":"regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-for-more-information-regn-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-for-more-information-regn-2\/","title":{"rendered":"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations \u2013 Investors Should Contact Levi & Korsinsky for More Information \u2013 REGN"},"content":{"rendered":"
\n

NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc.<\/strong> (“Regeneron” or the “Company”) (NASDAQ: REGN) of a class action securities lawsuit.<\/p>\n

\n CLASS DEFINITION: <\/strong>The lawsuit seeks to recover losses on behalf of Regeneron investors who were adversely affected by alleged securities fraud between November 2, 2023 and October 30, 2024. Follow the link below to get more information and be contacted by a member of our team:<\/p>\n

\n https:\/\/zlk.com\/pslra-1\/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=130893&wire=3<\/a>\n <\/p>\n

\n REGN<\/strong> investors may also contact Joseph E. Levi, Esq. via email at\u00a0jlevi@levikorsinsky.com<\/a>\u00a0or by telephone at (212) 363-7500.<\/p>\n

\n CASE DETAILS: <\/strong>The filed complaint alleges that defendants made false statements and\/or concealed that: (1) Regeneron paid credit card fees to distributors on the condition that distributors did not charge, one of the Company\u2019s primary products, Eylea customers more to use a credit card; (2) these payments subsidized the prices that customers paid when using credit cards to purchase Eylea; (3) as a result, Regeneron offered a price concession that lowered Eylea\u2019s selling price; (4) because retina practices were sensitive to higher prices when using credit cards to purchase anti-VEGF medications, Regeneron\u2019s price concessions provided a competitive advantage; (5) as a result of the foregoing, Regeneron misleadingly boosted reported Eylea sales; (6) by failing to report its payment of credit card fees as price concessions, Regeneron overstated the ASP reported to federal agencies, thereby violating the False Claims Act; and (7) as a result of the foregoing, defendants\u2019 positive statements about the Company\u2019s business, operations, and prospects were materially misleading and\/or lacked a reasonable basis.<\/p>\n

\n WHAT’S NEXT? <\/strong>If you suffered a loss in Regeneron during the relevant time frame, you have until March 10, 2025<\/strong>\u00a0to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.<\/p>\n

\n NO COST TO YOU: <\/strong>If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.<\/strong><\/p>\n

\n WHY LEVI & KORSINSKY: <\/strong>Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services\u2019 Top 50 Report as one of the top securities litigation firms in the United States.<\/p>\n

\n CONTACT:<\/strong>
\n
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com<\/a>\u00a0
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com<\/a>\u00a0<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Regeneron investors who were adversely affected by alleged securities fraud between November 2, 2023 and October 30, 2024. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=130893&wire=3 REGN investors may also contact Joseph E. Levi, Esq. via email at\u00a0jlevi@levikorsinsky.com\u00a0or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and\/or concealed that: (1) Regeneron paid credit card fees to distributors on the condition that … <\/p>\n

Continue reading “Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations \u2013 Investors Should Contact Levi & Korsinsky for More Information \u2013 REGN”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-816328","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nRegeneron Pharmaceuticals, Inc. Sued for Securities Law Violations \u2013 Investors Should Contact Levi & Korsinsky for More Information \u2013 REGN - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-for-more-information-regn-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations \u2013 Investors Should Contact Levi & Korsinsky for More Information \u2013 REGN - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Regeneron investors who were adversely affected by alleged securities fraud between November 2, 2023 and October 30, 2024. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=130893&wire=3 REGN investors may also contact Joseph E. Levi, Esq. via email at\u00a0jlevi@levikorsinsky.com\u00a0or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and\/or concealed that: (1) Regeneron paid credit card fees to distributors on the condition that … Continue reading "Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations \u2013 Investors Should Contact Levi & Korsinsky for More Information \u2013 REGN"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-for-more-information-regn-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-21T18:47:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MjA3NCM2NzYxMzY5IzIwMjA0MjY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-for-more-information-regn-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-for-more-information-regn-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations \u2013 Investors Should Contact Levi & Korsinsky for More Information \u2013 REGN\",\"datePublished\":\"2025-02-21T18:47:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-for-more-information-regn-2\\\/\"},\"wordCount\":469,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-for-more-information-regn-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MjA3NCM2NzYxMzY5IzIwMjA0MjY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-for-more-information-regn-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-for-more-information-regn-2\\\/\",\"name\":\"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations \u2013 Investors Should Contact Levi & Korsinsky for More Information \u2013 REGN - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-for-more-information-regn-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-for-more-information-regn-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MjA3NCM2NzYxMzY5IzIwMjA0MjY=\",\"datePublished\":\"2025-02-21T18:47:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-for-more-information-regn-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-for-more-information-regn-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-for-more-information-regn-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MjA3NCM2NzYxMzY5IzIwMjA0MjY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MjA3NCM2NzYxMzY5IzIwMjA0MjY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-for-more-information-regn-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations \u2013 Investors Should Contact Levi & Korsinsky for More Information \u2013 REGN\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations \u2013 Investors Should Contact Levi & Korsinsky for More Information \u2013 REGN - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-for-more-information-regn-2\/","og_locale":"en_US","og_type":"article","og_title":"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations \u2013 Investors Should Contact Levi & Korsinsky for More Information \u2013 REGN - Market Newsdesk","og_description":"NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Regeneron investors who were adversely affected by alleged securities fraud between November 2, 2023 and October 30, 2024. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/regeneron-pharmaceuticals-inc-lawsuit-submission-form?prid=130893&wire=3 REGN investors may also contact Joseph E. Levi, Esq. via email at\u00a0jlevi@levikorsinsky.com\u00a0or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and\/or concealed that: (1) Regeneron paid credit card fees to distributors on the condition that … Continue reading \"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations \u2013 Investors Should Contact Levi & Korsinsky for More Information \u2013 REGN\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-for-more-information-regn-2\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-21T18:47:16+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MjA3NCM2NzYxMzY5IzIwMjA0MjY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-for-more-information-regn-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-for-more-information-regn-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations \u2013 Investors Should Contact Levi & Korsinsky for More Information \u2013 REGN","datePublished":"2025-02-21T18:47:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-for-more-information-regn-2\/"},"wordCount":469,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-for-more-information-regn-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MjA3NCM2NzYxMzY5IzIwMjA0MjY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-for-more-information-regn-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-for-more-information-regn-2\/","name":"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations \u2013 Investors Should Contact Levi & Korsinsky for More Information \u2013 REGN - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-for-more-information-regn-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-for-more-information-regn-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MjA3NCM2NzYxMzY5IzIwMjA0MjY=","datePublished":"2025-02-21T18:47:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-for-more-information-regn-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-for-more-information-regn-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-for-more-information-regn-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MjA3NCM2NzYxMzY5IzIwMjA0MjY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MjA3NCM2NzYxMzY5IzIwMjA0MjY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/regeneron-pharmaceuticals-inc-sued-for-securities-law-violations-investors-should-contact-levi-korsinsky-for-more-information-regn-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations \u2013 Investors Should Contact Levi & Korsinsky for More Information \u2013 REGN"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/816328","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=816328"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/816328\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=816328"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=816328"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=816328"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}